When DSS-treated animals are given a 5-LOX inhibitor or an LTB4 antagonist, colonic shortening as well as histological and inflammatory scores were improved in the mouse model of colonic inflammation [9,11,12,13]. This evidence concerns the gene ALOX5 and colitis.